Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1996-11-15
2000-11-14
Bernhardt, Emily
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
549245, 549338, 549343, A61K 31495, C07D48722
Patent
active
061470767
ABSTRACT:
The present invention provides a compound having the structure: ##STR1## wherein R.sub.1 R.sub.6 and R.sub.7 are independently hydrogen, OH, NH.sub.2, SH, halogen, C.sub.1 -C.sub.9 linear or branched chain alkyl, alkylmercapto, alkylamino, dialkylamino, alkoxy, phenyl, etc.; wherein R.sub.0 and R.sub.2 are independently hydrogen, OH, linear or branched chain alkyl, --CR.sub.3 R.sub.3 --CH(O)CH.sub.2, --CR.sub.3 R.sub.3 --CH.sub.2 CH.sub.3, --CR.sub.3 R.sub.3 --CH.sub.2 CH.sub.2 OH, --CR.sub.3 R.sub.3 --CH(OH)R.sub.4 or --CR.sub.3 R.sub.3 --CH.dbd.CHR.sub.4 ; wherein R.sub.3 and R.sub.4 are independently hydrogen, halogen, C.sub.1 -C.sub.9 linear or branched chain alkyl, phenyl, etc.; wherein R.sub.5 is hydrogen, C.sub.1 -C.sub.9 linear or branched chain alkyl, phenyl, etc.; and wherein R.sub.8 is hydrogen, C.sub.1 -C.sub.9 linear or branched chain acyl, benzoyl, etc.; with the proviso that (a) when R.sub.2 is --CR.sub.3 R.sub.3 --CH(O)CH.sub.2, --CR.sub.3 R.sub.3 --CH.sub.2 CH.sub.3, --CR.sub.3 R.sub.3 --CH.sub.2 CH.sub.2 OH, --CR.sub.3 R.sub.3 --CH(OH)R.sub.4 or --CR.sub.3 R.sub.3 --CH.dbd.CHR.sub.4, then R.sub.2 is hydrogen; (b) when R.sub.0 is --CR.sub.3 R.sub.3 --CH(O)CH.sub.2, --CR.sub.3 R.sub.3 --CH.sub.2 CH.sub.3, --CR.sub.3 R.sub.3 --CH.sub.2 CH.sub.2 OH, --CR.sub.3 R.sub.3 --CH(OH)R.sub.4 or --CR.sub.3 R.sub.3 --CH.dbd.CHR.sub.4, then R.sub.2 is OH; and (c) when (i) R.sub.0 or R.sub.2 is --CR.sub.3 R.sub.3 --CH.dbd.CHR.sub.4, (ii) R.sub.3 and R.sub.5 are CH.sub.3 and (iii) R.sub.4 is hydrogen, then R.sub.1, R.sub.6 and R.sub.7 are not all hydrogen. Also provided are related compounds and compositions, and methods of inhibiting the growth of multidrug resistant cells by means of MDR reversal, collateral sensitivity and quantitative synergism.
REFERENCES:
patent: 5284947 (1994-02-01), Kadam et al.
patent: 5338726 (1994-08-01), Shiosaki et al.
patent: 5338845 (1994-08-01), Barrow et al.
Chemical Abstracts, 100:33257, Jan. 30, 1984, Fujisawa Pharmaceutical Co.
Chemical Abstracts, 103:87904, Sep. 16, 1985., Fujisawa Pharmaceutical Co.
Chemical Abstracts, 103:101553, Sep. 3, 1985, Laws et al.
Chemical Abstracts, 108:164470, May 9, 1988, Hodge et al.
Bellamy et al, Cancer Investigation 8(5), pp. 547-562 (1990).
Advanced Organic Chemistry (2nd Ed.) by Jerry March, pp. 485-489, 1977.
Takase, S., et al., J. Antibiot, 37, 1320 (1984.
Takase, S., et al., Tetrahedron, 42, 5887 (1986).
Karwowski, H.P., et al., J. Antibiot, 46, 374 (1993).
Hochlowski, J.E., et al., J. Antibiot, 46, 380 (1993).
Shinohara, C., et al., J. Antibiot, 47, 163 (1994).
Hino, T., et al., Chem Pharm Bull, 33, 5202 (1985).
Massden, S.P., et al. J. Am. Chem. Soc., 116, 11143 (1994).
Parsons, R.L., et al., J. Org. Chem., 58 7482 (1993).
Arai et al., Chem. Pharm. Bull., 37:2937-2939, 1989.
Takase et al., Tetrahedron Letters, 25:4673-4676, 1984.
Bornmann William
Chou Ting Chao
Danishefsky Samuel J.
Depew Kristopher
Marsden Stephen P.
Bernhardt Emily
Sloan-Kettering Institute for Cancer Research
The Trustees of Columbia University in the City of New York
LandOfFree
Analogues of N-acetylardeemin, method of preparation and uses th does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Analogues of N-acetylardeemin, method of preparation and uses th, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Analogues of N-acetylardeemin, method of preparation and uses th will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2065656